Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1989 1
1990 3
1993 1
1997 1
2004 1
2013 1
2016 2
2017 1
2018 1
2020 2
2021 5
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
Grunenberg A, Kaiser LM, Woelfle S, Schmelzle B, Viardot A, Möller P, Barth TFE, Muche R, Dreyhaupt J, Raderer M, Kiesewetter B, Buske C. Grunenberg A, et al. Among authors: kaiser lm. BMC Cancer. 2021 Jun 29;21(1):749. doi: 10.1186/s12885-021-08464-6. BMC Cancer. 2021. PMID: 34187401 Free PMC article. Clinical Trial.
Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus.
Cusan M, Vegi NM, Mulaw MA, Bamezai S, Kaiser LM, Deshpande AJ, Greif PA, Quintanilla-Fend L, Göllner S, Müller-Tidow C, Humphries KR, Armstrong SA, Hiddemann W, Feuring-Buske M, Buske C. Cusan M, et al. Among authors: kaiser lm. Blood. 2017 Jan 19;129(3):319-323. doi: 10.1182/blood-2016-04-706978. Epub 2016 Nov 8. Blood. 2017. PMID: 27827825 Free article.
19 results